Purpose: Lack of control for time-varying exposures can lead to substantial bias in estimates of treatment effects. The aim of this study is to provide an overview and guidance on some of the available methodologies used to address problems related to time-varying exposure and confounding in pharmacoepidemiology and other observational studies. The methods are explored from a conceptual rather than an analytical perspective.
which has given rise a need to understand better the methods that meet these challenges, and develop new methods if gaps exist. The aim of this article is to review some of the methods proposed in the literature and provide a guide for researchers who encounter these problems in longitudinal pharmacoepidemiological and other observational studies. This work also aims to open a dialogue about the methodological areas less frequently pursued and identify areas that need further methodological developments. Although there is a conceptual difference, for practical reasons in the remainder of the article, the terms treatment and exposure are used interchangeably, as are outcome and response.
In pharmacoepidemiological and other observational studies, the exposure may be a single event, but may often be prolonged and vary over time, with one or more exposure periods. However, even in the latter case, exposure is often defined only as a baseline covariate.
When the focus of the investigation is to consider multiple exposures over time, then all the time-dependent changes of the involved factors, including confounders, should be taken into account.
In a data structure with time dependency, a variety of issues can arise simultaneously, ranging from a more complex exposure definition to the identification and application of proper statistical methods for time-varying exposure and covariates. For simplicity of exposition in the article, the problems are explored one at a time. Specifically, the focus is on the following issues: treatment episode construction, time-varying confounders, cumulative exposure and latency, and treatment switching.
The exposure definition in a time-varying context is complex, and different definitions can lead to the construction of different treatment episodes and potentially different conclusions to the same research question; bias can also be inadvertently introduced.
Therefore, it is critically important to define treatment episodes that reflect the actual exposure of the subjects, i.e., exhibiting as little misclassification as possible, which requires the researcher to handle multiple methodological issues. In pharmacoepidemiological studies, one such issue derives from the fact that the available information about exposure, i.e., subjects' actual drug intake, is often limited in registers of dispensed or prescribed drugs. For practical purposes in the following, the term prescription is used to mean both prescription and dispensing.
Usually in prescription registers only the date and amount prescribed and rarely information about the prescribed dosage is known. For each prescription, an exposure period can be assigned based on this information. Variation in drug intake and other factors may lead to irregular patterns, and temporal gaps between or overlaps of prescriptions. A gap is defined as the number of days between the end of supply from one prescription and the start of the subsequent prescription.
Conversely, an overlap is the number of days overlapping between two consecutive prescriptions. 1 As gaps and overlaps commonly occur in practice, it is important to take these into account in the construction of treatment episodes based on multiple prescriptions.
The dosage or duration of the treatment, or more generally the exposure to it, which can vary over time, is an additional consideration.
Dynamic treatment regimens are usually, but not only, dependent on the patient response to the drugs. In this case, there is often a presence of time-dependent confounding factors that are affected by the previous exposure levels, and thus act as intermediates in the causal pathway between the exposure and the outcome of interest. 2 When a confounding factor is also an intermediate between the exposure and the response variable, standard statistical methods may lead to biased estimates of the effect of interest.
Because studies are often focused on treatment effect (adverse and/or beneficial), the researcher needs to take into account the cumulative exposure to the treatment (i.e., dose and duration) when the exposure varies over time. For some outcomes, it may be reasonable to classify subjects dichotomously as exposed or not exposed.
For other outcomes, however, the amount of exposure is crucial. The evaluation of a treatment effect or an exposure-outcome association in this scenario depends strongly on the time since exposure 3 and the particular outcome of interest.
Finally, there is the issue that patients often switch to alternative treatments. The reasons for the switch can vary, ranging from side effects, unwillingness to continue, physician's suggestion, or participation in clinical trials, where the switch is allowed by experimental design. 4, 5 In the evaluation of treatment effects or associations, the underlying switching mechanism should then be properly considered.
For each of the above problems, different methods have been proposed and applied. The validity of inference for each method relies on certain assumptions, and each method has its strengths and weaknesses. The range of methods includes simpler techniques, such as an intention-to-treat (ITT) analysis which only considers baseline exposure and does not adjust for the confounding related to the problems described above, to the more structured but less intuitive methods such as structural nested failure time models (SNFTMs) which adjusts for time-varying confounders 6 or switching. The present article
KEY POINTS
• In longitudinal pharmacoepidemiological and other observational studies, construction of proper treatment episodes and correct modelling for time-varying confounders, cumulative exposure and latency, and treatment switching are essential.
• Several methods have been proposed in the literature to address problems related to time-varying exposure and confounding in pharmacoepidemiological and other observational studies.
• The most advanced approaches such as marginal structural models or structural nested failure time models should be used to analyse longitudinal data with time-varying covariates in the presence of timevarying confounders or switching after taking into account the involved assumptions.
• Further research on the application and implementation of the most advanced methods is needed.
• Different methods can lead to substantial differences in the estimates of the associations or effects of interest; therefore, implementation of different methods and comparison of the results are recommended.
provides an overview of some of the methods that have been proposed to account for important time-varying exposure related problems: treatment episodes construction, time-varying confounders, cumulative exposure and latency, and treatment switching. For each of the problems, the identified methodologies are described from a conceptual but not an analytical perspective.
In Table 1 , a summary of the challenges and related applied examples is provided. For each of the described methods, a short description of the main strengths and limitations is provided in Table 2 , whereas in Table 3 , references to the software for some of the most complex methods are reported.
| METHODS
The starting point of the study was a literature search of studies investigating or applying methodologies for time-varying exposure using relevant keywords such as time-dependent, time-varying, time to event, time to treatment, and treatment switching. By viewing the abstracts, we retained the resulting articles that were relevant to the four topics of interest, construction of treatment episodes, time-varying confounders, cumulative exposure and latency, and treatment switching. A consistency among the references of some key methodological articles led to the identification of the most frequently referenced methods for the investigated problems. By checking the cited articles, we attempted to find other relevant publications. Lastly,
we searched for published studies in which the identified methods were used.
| METHODS FOR CONSTRUCTION OF TREATMENT EPISODES
Observational studies are becoming increasingly important for answering pharmacoepidemiological questions, which may not be readily answered by randomised clinical trials because of their known limitations (such as small population, selected patients, and short followup) and for practical reasons including complexity, costs, and ethical
issues. An observational study to investigate drug effects or associations with some outcome of interest can be performed as a record linkage study of a drug prescription register with a patient register, containing individual level longitudinal data on both drug exposure and diagnoses. On the other hand, constructing well-defined treatment episodes from prescription registers, for the individuals under study, is challenging.
Many problems arise because the registers usually do not contain all the information about the dose and the duration of a treatment prescribed to a patient. As a result, the treatment episodes often need to be estimated on the basis of the purchasing date, when available, and quantity. 7 Data on purchased quantities of drug do not usually provide the researcher with additional information about the intended indication for the use of the drugs, the daily quantity used, and the duration of the treatment. Moreover, investigators encounter temporal gaps and overlaps among prescriptions in the attempt to construct treatment episodes for a patient, and using different methods accounting for such problems may lead to different estimates of drug effects. We will ignore, for simplification, any discussion of capturing how the patient actually consumes the medication (consistently each day, varying dose or frequency, etc). In a follow-up study of antidepressant drug users, Gardarsdottir et al. 1 showed that different methods accounting for different lengths of gaps and overlaps between prescriptions led to different treatment episodes estimates.
Time-varying confounders
In studies investigating time-varying exposure, there may be a presence of time-varying confounders affected by previous exposure levels, i.e., acting as intermediates in the pathway between exposure and outcome.
In studying the effect of a drug to reduce glycaemia levels in type II diabetes patients on the onset of cardiac events, a measure of the blood glucose levels (HbA 1c ) can both be affected by previous treatment dose and affect the outcome (high HbA 1c may increase the drug dosage and the risk of cardiac event). See Daniel et al. 2 for a detailed description of the mechanism.
Cumulative exposure and latency
Dose and duration of exposure accumulated over time may increase or decrease the effect on the outcome. It should be considered that different outcomes have different latent periods (time to initiation of the treatment to diagnosis). Therefore, different drugs require different exposure periods in relation to the latency. However, these latent periods are usually unknown, and a long follow-up period allows different assumptions about latent period to be tested.
Sylvestre et al. 3 showed that the magnitude of the effect of a psychotropic drug prescribed to treat insomnia and fallrelated injuries was strictly related to the cumulated dose and time since exposure to it.
Treatment switching
Individuals exposed to a treatment can switch to an alternative during the follow-up time. When considering a time-varying exposure the switching process complicates the estimation of treatment effects because it cannot be considered a random mechanism. When individuals are not under the initial treatment during the entire follow-up, the method to use in the investigation should account for it.
Diaz et al. 4 used different methods accounting for switching to show the differences in treatment effect estimates in an indirect comparison between renal cell carcinoma drugs. Facilitation of international comparisons.
The drug under study could be prescribed with a dosage different from the average, with an indication other than the main, and/or in children.
-accounting for gaps and overlaps
Predefined length for allowed gaps (based on prior knowledge on drug utilisation). Overlapping days can be added to the treatment episode duration or ignored.
Estimations of treatment episodes accounting for gaps and overlaps drive to a more accurate exposure definition and allow the consideration of the nature of the treatment under study when deciding on the length of gaps and the way to account for overlaps.
Particular attention needs to be paid in choosing the predefined length for the allowed gap and the way to account for overlaps. When the assumptions on gaps and overlaps are distant from the real drug utilisation, the treatment episodes estimates may be biased.
-prospectively filling gaps
Predefined length for allowed gaps.
Assuming gaps of a fixed number of days avoids the immortal bias that could be introduced if the allowed gaps would depend by future prescriptions. The time between the two subsequent prescriptions would be risk-free (immortal) time.
Particular attention needs to be paid in choosing the predefined length for the allowed gap trying to emulate the real drug utilisation patterns.
Time-varying confounders

Main assumptions Main strengths Main limitations
-methods without any adjustment strategy
There are no time-varying confounders or they can be treated as baseline.
Simplicity of application. The time dependency of the variables involved in the study is not considered introducing bias in the treatment effect estimates.
-time-varying covariates and propensity scores methods Time-varying confounders are not intermediate factors.
Accounting for the time dependency of the confounders. Simplicity of the application.
Not accounting for the potential role of intermediate that a confounder can assume in a time-varying analysis.
-MSMs Stable unit treatment, positivity, and no unmeasured confounders.
Controlling for time-varying confounders without conditioning on them. Natural extension of Cox and logistic models.
The no unmeasured confounders assumption requires information on all the variables of interest for the study. The complexity of application with respect to standard methods limits the availability of statistical packages.
-SNFTMs Stable unit treatment, positivity, and no unmeasured confounders.
Interactions between time-varying covariates and treatment can be included in the model. Efficiency.
The no unmeasured confounders assumption requires information on all the variables of interest for the study. Computationally intensive. The complexity of application with respect to standard methods limits the availability of statistical packages.
Cumulative exposure and latency
Main assumptions Main strengths Main limitations
The amount in dose and duration of exposure does not affect the outcome and can be ignored.
Simplicity of application. Undervaluation of the importance of all the aspects of the magnitude of exposure.
-WCD models The form of the weight function has to be estimated using cubic regression B-splines.
It accounts for the quantity of exposure and the time since exposure.
-fractional polynomials 
Treatment switching
Main assumptions Main strengths Main limitations
The switching is a random ignorable mechanism.
Simplicity of application.
Ignoring that switch can affect the treatment effect estimates.
(Continues)
Several methods have been proposed in applications covering different therapeutic areas to control for this type of information bias.
However, there is still a lack of more homogeneous guidelines on how to construct treatment episodes, which could facilitate, among other things, the international comparison of drug effectiveness and safety studies. Because of the current methodological differences in the construction of the treatment episodes, the comparison among studies for the same exposure-response association becomes difficult, if not impossible. In the following of the section, some of the methods used to define the exposure to a treatment, considering different aspects involved, are described.
| Methods using the defined daily dose (DDD) assumption
When there is no information about the prescribed dosage, a common approach is to assume that the patients take 1 DDD of the prescribed drug per day. [8] [9] [10] [11] The formal definition of the DDD 
| Methods accounting for overlaps and gaps between drug prescriptions
It has been shown that the presence of a gap between prescriptions does not with certainty indicate the absence of drug consumption. 16 Conversely, for practical reasons, patients may collect new medications before finishing the previously purchased quantity, thus introducing in prescription registers the so-called overlaps. Gardarsdottir et al.
observed that using different methods to account for temporal gaps and overlaps between prescriptions may lead to different estimates of The switching is a random ignorable mechanism.
-models with a time-varying covariate for the switch
The switch is not affected by previous treatment levels.
Ignoring that switch can be affected by the treatment while affecting the outcome.
-MSMs with IPCW Stable unit treatment, positivity, and no unmeasured confounders.
Emulation of the population in absence of switching. Accounting, in the treatment effect estimates, for what would have happened in absence of switching.
The survival can be derived accounting also for the counterfactual event times of the switchers emulating what would have happened at the treatment effects in the absence of switching.
The no unmeasured confounders assumption requires information on all the variables of interest for the study. Computational intensive. The complexity of application with respect to standard methods limits the availability of statistical packages.
For all the probabilistic models involved in the above methods, a further assumption of correct model specification must be considered. -SNFTMs The code that can be used as a reference for implementing a SNFTM is available at the website of the Harvard School of Public Health (https:// www.hsph.harvard.edu/causal/software/).
-WCD models The R package WCE is available in the Comprehensive R Archive Network (CRAN) website (http://cran.rproject.org/web/packages/WCE).
-fractional polynomials
The R package mfp is available in the CRAN website (https://cran.r-project.org/web/packages/mfp/).
the treatment duration, and hence different conclusions on the effectiveness and safety of a drug. One method took into account the over- 
| Method of prospectively filling gaps
In many pharmacoepidemiological investigations, the study design is driven by the use of pre-existing data, and more specifically the study population is derived from a retrospective exposure-based cohort. In this type of study, the individuals under observation are identified after the exposure definition. Because the data already exist, often investigators define the exposure by looking at data for the entire observation period. In such a process, gaps present in prescription data can be filled retrospectively if the patients have subsequent drug prescriptions for the same kind of medication. The approach of exploring the data to define the exposure may lead to a particular type of bias resulting from the fact that the temporal gaps among prescriptions can be related to the future of the patients' behaviours with respect to the treatment and to the outcome under investigation. 17 In such a way, the exposure definition is affected by future circumstances, and the allowed gaps become risk-free time, leading to an underestimation of the effect or association. This is often referred to as immortal time bias. 13, 18, 19 The method proposed to avoid this kind of bias is a prospective filling of the gaps. With this method, a subject under study is considered exposed until the moment the last dispensed supply is 
| Marginal structural models
Marginal structural models (MSMs) [30] [31] [32] are mainly, but not exclusively, observational-based methods and an important statistical tool proposed by Robins to adjust for time-varying confounders. These models work under an extension for longitudinal data, of the potential outcomes framework proposed by Rubin. 33 One of the most common and intuitive ways to estimate the parameters of a MSM is using the inverse probability of treatment weighted estimator (IPTW). The IPTW method enables accounting for both baseline and time-varying confounders. A weighting system gives each unit under observation a weight corresponding to an inverse function of the probability to be exposed conditional on the history of the previous level of the exposure and baseline and time-varying confounders. In the stabilised weights, the numerator is given by the probability of being exposed conditional on the history of the previous level of the exposure and only baseline confounders. To reduce the variability deriving by dominant subjects in the study, stabilised weights are recommended rather than the "non-stabilised" weights (with numerator equal to tion procedure. 41 The g-estimation procedure has been less popular in applications, probably due to the computational intensity and the low intuitiveness with respect to the more applied MSMs. 42 Moreover, while for some outcomes being exposed once is sufficient to consider the subject as exposed, the exposure to high cumulative duration or high cumulative dose is crucial for the majority of the associations. Consequently, the exposure definition and the temporal window considered should be a function of the particular outcome of interest in the plan of a study. For example, a short follow-up would be sufficient, and simple estimation methods can be appropriate to investigate the association between a certain type of drug and allergic reactions or infections. However, a longer follow-up and consequently more advanced methods are needed in investigating the association between a drug and a long-term outcome, such as cancer. Several methods have been introduced which attempt to model a cumulative exposure and the latency, from less flexible approaches where the latency needs to be specified by a prior parametric function, 44 to more flexible approaches where the latency is modelled with flexible cubic splines techniques. 45, 46 In the next section, some of these methods are discussed.
| Methods without any adjustment strategy
Considering the problem of interest related to outcomes that occur in long term after the exposure, the use of models that do not take into account in any way the time since exposure and the magnitude of the exposure will produce biased results. Moreover, the outcome of interest should be properly considered in the study design. In this sense, when data are available, the duration of the follow-up should be appropriate for the outcome. The use of the same temporal window, for example, to investigate the effect of a particular treatment on the onset of allergic reactions and cancers will not be a good practice, because this approach will assume that time since exposure, duration of exposure, and cumulative dose have the same effect on both outcomes. A non-acute adverse outcome such as cancer can be developed many years after the beginning of the exposure, requiring longer follow-up and quantification of the exposure, whereas an acute allergic reaction can occur shortly after the first dose, requiring shorter follow-up and a simpler exposure definition. 
5.2
| METHODS FOR TREATMENT SWITCHING
In longitudinal studies assessing a treatment effect, the fact that patients can switch treatment during the follow-up is a common issue.
The reasons for switching can be different, ranging from adverse reactions, failure of therapeutic effects, to the individual behaviour of the patient in the compliance to the treatment. 49 The DAG for the time- 
| Excluding and censoring switchers
Another category of methods evaluates the treatment effect excluding or censoring switchers from the analysis. Like methods without any adjustment strategy, the main assumption behind these approaches is that the switching happens at random such that it can be ignored in the investigation. Excluding and censoring switchers assume that there are no confounders that affect both the switch and the outcome, and moreover censoring switchers is equivalent to assuming that the censoring is not informative, in such a way that it is not related to the outcome. 4 This is not a valid assumption and it may cause bias.
| Models with time-varying covariates
In some applications, the switch is added to a regression model as a 
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